Molecular mechanisms of childhood overgrowth

American Journal of Medical Genetics, Part C: Seminars in Medical Genetics

Volumn 163, Issue 2, 2013, Pages 71-75

  Tatton Brown, Katrina ^a   Weksberg, Rosanna ^b  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN SERINE THREONINE KINASE;

AKT3 GENE; APOPTOSIS; BECKWITH WIEDEMANN SYNDROME; CELL GROWTH; CELL SURVIVAL; CHILDHOOD OVERGROWTH DISORDER; CHROMOSOME; DIS3L2 GENE; EDITORIAL; EPIGENETICS; EZH2 GENE; GENE; GENE CLUSTER; GENE CONTROL; GENE MUTATION; GENETIC DISORDER; GENOME IMPRINTING; GENOTYPE; GPC3 GENE; GROWTH DISORDER; HAMARTOMA; HAMARTOMA TUMOR SYNDROME; HUMAN; MEGALENCEPHALY CAPILLARY MALFORMATION; MEGALENCEPHALY POLYDACTYLY POLYMICROGYRIA HYDROCEPHALUS SYNDROME; MOLECULAR PATHOLOGY; MOSAIC REGIONAL OVERGROWTH DISORDER; MULTIPLE CANCER; NSD1 GENE; PERLMAN SYNDROME; PHENOTYPE; PIK3CA GENE; PIK3R2 GENE; PRIORITY JOURNAL; PROTEIN SYNTHESIS; PTEN GENE; RISK FACTOR; SIMPSON GOLABI BEHMEL SYNDROME; SOMATIC GENE THERAPY;

CHILD; GENE EXPRESSION PROFILING; GROWTH; HUMANS;

EID: 84876809682     PISSN: 15524868     EISSN: 15524876     Source Type: Journal    
DOI: 10.1002/ajmg.c.31362     Document Type: Editorial

References (32)

1. Arch EM, Goodman BK, Van Wesep RA, Liaw D, Clarke K, Parsons R, McKusick VA, Geraghty MT. 1997. Deletion of PTEN in a patient with Bannayan-Riley-Ruvalcaba syndrome suggests allelism with Cowden disease. Am J Med Genet 71:489-493.
2. Astuti D, Morris MR, Cooper WN, Staals RH, Wake NC, Fews GA, Gill H, Gentle D, Shuib S, Ricketts CJ, Cole T, van Essen AJ, van Lingen RA, Neri G, Opitz JM, Rump P, Stolte-Dijkstra I, Muller F, Pruijn GJ, Latif F, Maher ER. 2012. Germline mutations in DIS3L2 cause the Perlman syndrome of overgrowth and Wilms tumor susceptibility. Nat Genet 44:277-284.
3. Beighton P, Emery AE. 1988. Inherited disorders of the skeleton. Churchill Livingstone: Edinburgh.
4. Biesecker L. 2006. The challenges of Proteus syndrome: Diagnosis and management. Eur J Hum Genet 14:1151-1157.
5. Birkenkamp KU, Coffer PJ. 2003. Regulation of cell survival and proliferation by the FOXO (Forkhead box, class O) subfamily of Forkhead transcription factors. Biochem Soc Trans 31:292-297.
6. Chalhoub N, Baker SJ. 2009. PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol 4:127-150.
7. Cohen MM Jr. 1982. The large-for-gestational-age (LGA) infant in dysmorphic perspective. Clin Genet 153.
8. Douglas J, Cilliers D, Coleman K, Tatton-Brown K, Barker K, Bernhard B, Burn J, Huson S, Josifova D, Lacombe D, Malik M, Mansour S, Reid E, Cormier-Daire V, Cole T, Rahman N. 2007. Mutations in RNF135, a gene within the NF1 microdeletion region, cause phenotypic abnormalities including overgrowth. Nat Genet 39:963-965.
9. Engelman JA, Luo J, Cantley LC. 2006. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 7:606-619.
10. Gibson WT, Hood RL, Zhan SH, Bulman DE, Fejes AP, Moore R, Mungall AJ, Eydoux P, Babul-Hirji R, An J, Marra MA, Chitayat D, Boycott KM, Weaver DD, Jones SJ. 2012. Mutations in EZH2 cause Weaver syndrome. Am J Hum Genet 90:110-118.
11. Happle R. 1987. Lethal genes surviving by mosaicism: A possible explanation for sporadic birth defects involving the skin. J Am Acad Dermatol 16:899-906.
12. Kosaki R, Fujita H, Ueoka K, Torii C, Kosaki K. 2011. Overgrowth of prenatal onset associated with submicroscopic 9q22.3 deletion. Am J Med Genet Part A 155A:903-905.
13. Kurotaki N, Imaizumi K, Harada N, Masuno M, Kondoh T, Nagai T, Ohashi H, Naritomi K, Tsukahara M, Makita Y, Sugimoto T, Sonoda T, Hasegawa T, Chinen Y, Tomita Ha HA, Kinoshita A, Mizuguchi T, Yoshiura Ki K, Ohta T, Kishino T, Fukushima Y, Niikawa N, Matsumoto N. 2002. Haploinsufficiency of NSD1 causes Sotos syndrome. Nat Genet 30:365-366.
14. Lindhurst MJ, Sapp JC, Teer JK, Johnston JJ, Finn EM, Peters K, Turner J, Cannons JL, Bick D, Blakemore L, Blumhorst C, Brockmann K, Calder P, Cherman N, Deardorff MA, Everman DB, Golas G, Greenstein RM, Kato BM, Keppler-Noreuil KM, Kuznetsov SA, Miyamoto RT, Newman K, Ng D, O'Brien K, Rothenberg S, Schwartzentruber DJ, Singhal V, Tirabosco R, Upton J, Wientroub S, Zackai EH, Hoag K, Whitewood-Neal T, Robey PG, Schwartzberg PL, Darling TN, Tosi LL, Mullikin JC, Biesecker LG. 2011. A mosaic activating mutation in AKT1 associated with the Proteus syndrome. N Engl J Med 365:611-619.
15. Malan V, Chevallier S, Soler G, Coubes C, Lacombe D, Pasquier L, Soulier J, Morichon-Delvallez N, Turleau C, Munnich A, Romana S, Vekemans M, Cormier-Daire V, Colleaux L. 2010a. Array-based comparative genomic hybridization identifies a high frequency of copy number variations in patients with syndromic overgrowth. Eur J Hum Genet 18:227-232.
16. Malan V, Rajan D, Thomas S, Shaw AC, Louis Dit Picard H, Layet V, Till M, van Haeringen A, Mortier G, Nampoothiri S, Puseljic S, Legeai-Mallet L, Carter NP, Vekemans M, Munnich A, Hennekam RC, Colleaux L, Cormier-Daire V. 2010b. Distinct effects of allelic NFIX mutations on nonsense-mediated mRNA decay engender either a Sotos-like or a Marshall-Smith syndrome. Am J Hum Genet 87:189-198.
17. Manning BD, Tee AR, Logsdon MN, Blenis J, Cantley LC. 2002. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol Cell 10:151-162.
18. Molin AM, Andrieux J, Koolen DA, Malan V, Carella M, Colleaux L, Cormier-Daire V, David A, de Leeuw N, Delobel B, Duban-Bedu B, Fischetto R, Flinter F, Kjaergaard S, Kok F, Krepischi AC, Le Caignec C, Ogilvie CM, Maia S, Mathieu-Dramard M, Munnich A, Palumbo O, Papadia F, Pfundt R, Reardon W, Receveur A, Rio M, Ronsbro Darling L, Rosenberg C, Sa J, Vallee L, Vincent-Delorme C, Zelante L, Bondeson ML, Anneren G. 2012. A novel microdeletion syndrome at 3q13.31 characterised by developmental delay, postnatal overgrowth, hypoplastic male genitals, and characteristic facial features. J Med Genet 49:104-109.
19. Partington MW, Fagan K, Soubjaki V, Turner G. 1997. Translocations involving 4p16.3 in three families: Deletion causing the Pitt-Rogers-Danks syndrome and duplication resulting in a new overgrowth syndrome. J Med Genet 34:719-728.
20. Phelan MC, Rogers RC, Saul RA, Stapleton GA, Sweet K, McDermid H, Shaw SR, Claytor J, Willis J, Kelly DP. 2001. 22q13 Deletion syndrome. Am J Med Genet 101:91-99.
21. Pilia G, Hughes-Benzie RM, MacKenzie A, Baybayan P, Chen EY, Huber R, Neri G, Cao A, Forabosco A, Schlessinger D. 1996. Mutations in GPC3, a glypican gene, cause the Simpson-Golabi-Behmel overgrowth syndrome. Nat Genet 12:241-247.
22. Redon R, Baujat G, Sanlaville D, Le Merrer M, Vekemans M, Munnich A, Carter NP, Cormier-Daire V, Colleaux L. 2006. Interstitial 9q22.3 microdeletion: Clinical and molecular characterisation of a newly recognized overgrowth syndrome. Eur J Hum Genet 14:759-767.
23. Riviere JB, Mirzaa GM, O'Roak BJ, Beddaoui M, Alcantara D, Conway RL, St-Onge J, Schwartzentruber JA, Gripp KW, Nikkel SM, Worthylake T, Sullivan CT, Ward TR, Butler HE, Kramer NA, Albrecht B, Armour CM, Armstrong L, Caluseriu O, Cytrynbaum C, Drolet BA, Innes AM, Lauzon JL, Lin AE, Mancini GM, Meschino WS, Reggin JD, Saggar AK, Lerman-Sagie T, Uyanik G, Weksberg R, Zirn B, Beaulieu CL, Majewski J, Bulman DE, O'Driscoll M, Shendure J, Graham JM Jr, Boycott KM, Dobyns WB. 2012. De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of related megalencephaly syndromes. Nat Genet 44:934-940.
24. Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H, Tempst P, Sabatini DM. 2004. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 14:1296-1302.
25. Sarbassov DD, Ali SM, Sabatini DM. 2005. Growing roles for the mTOR pathway. Curr Opin Cell Biol 17:596-603.
26. Shoukier M, Schroder J, Zoll B, Burfeind P, Freiberg C, Klinge L, Kriebel T, Lingen M, Mohr A, Brockmann K. 2012. A de novo interstitial deletion of 2p23.3-24.3 in a boy presenting with intellectual disability, overgrowth, dysmorphic features, skeletal myopathy, dilated cardiomyopathy. Am J Med Genet Part A 158A:429-433.
27. Stein RC. 2001. Prospects for phosphoinositide 3-kinase inhibition as a cancer treatment. Endocr Relat Cancer 8:237-248.
28. Tatton-Brown K, Pilz DT, Orstavik KH, Patton M, Barber JC, Collinson MN, Maloney VK, Huang S, Crolla JA, Marks K, Ormerod E, Thompson P, Nawaz Z, Lese-Martin C, Tomkins S, Waits P, Rahman N, McEntagart M. 2009. 15q Overgrowth syndrome: A newly recognized phenotype associated with overgrowth, learning difficulties, characteristic facial appearance, renal anomalies and increased dosage of distal chromosome 15q. Am J Med Genet Part A 149A:147-154.
29. Tatton-Brown K, Hanks S, Ruark E, Zachariou A, Duarte Sdel V, Ramsay E, Snape K, Murray A, Perdeaux ER, Seal S, Loveday C, Banka S, Clericuzio C, Flinter F, Magee A, McConnell V, Patton M, Raith W, Rankin J, Splitt M, Strenger V, Taylor C, Wheeler P, Temple KI, Cole T, Douglas J, Rahman N. 2011. Germline mutations in the oncogene EZH2 cause Weaver syndrome and increased human height. Oncotarget 2:1127-1133.
30. Tosca L, Brisset S, Petit FM, Metay C, Latour S, Lautier B, Lebas A, Druart L, Picone O, Mas AE, Prevot S, Tardieu M, Goossens M, Tachdjian G. 2011. Genotype-phenotype correlation in 13q13.3-q21.3 deletion. Eur J Med Genet 54:e489-e494.
31. Uliana V, Grosso S, Cioni M, Ariani F, Papa FT, Tamburello S, Rossi E, Katzaki E, Mucciolo M, Marozza A, Pollazzon M, Mencarelli MA, Mari F, Balestri P, Renieri A. 2010. 3.2Mb microdeletion in chromosome 7 bands q22.2-q22.3 associated with overgrowth and delayed bone age. Eur J Med Genet 53:168-170.
32. Weaver DD. 1994. Overgrowth syndromes and disorders: Definition, classification and discussion. Growth Gen Horm 10:1-4.